Egis To Develop Infrastructure With An Eye On More Production And Efficiency

Egis To Develop Infrastructure With An Eye On More Production And Efficiency

egis

As part of the continuation of a series of large-scale developments since 2019, leading pharmaceutical giant Egis Gyógyszergyár Zrt. now invests EUR 21.1 million in Körmend to install new technology, increase capacity and enhance efficiency. The investment is set to help the company not only produce more but also adapt to rapidly changing market needs better, and it also sets the stage for growth for decades to come.

Having a history of more than 100 years, Egis is one of the leading pharmaceutical companies in Hungary and Central and Eastern Europe. The corporation owned by the French Servier Group sells its products in around 60 countries.

The Körmend site alone is responsible for manufacturing 100 million boxes of medicine per year that is equivalent to nearly 60% of Egis’ finished goods. The announced investment expands this capacity further, but that is just one of the benefits. The pill plant and the packaging plant will both be developed, whereas the production infrastructure of galenicals, i.e. non-solid forms of medicine such as creams, gels, solutions and the like will be also renewed. The establishment of new quality assurance laboratories is in the pipeline as well.

egis

Preserving competitiveness is a priority to Egis, CEO Csaba Poroszlai said

Built in 2019, the state-of-the-art galenical plant will be fitted with new modern machinery thanks to which production is to become more economical and efficient, and Egis can get existing popular products on the market with new packaging in accordance with changed market needs.

Part of the plan is also to set up analytics and microbiology labs that will support the activity of the finished product plant. These facilities can contribute to Egis’ effort to expand its oncology portfolio.